Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  11/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 11/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
An Open Label Study Employing the Topical Immunomodulator Diphenylcyclopropenone in a Stabilized Gel to Treat Cutaneous Metastases
Status: Enrolling
Updated:  11/27/2017
Rockefeller University
mi
from
New York, NY
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
An Open Label Study Employing the Topical Immunomodulator Diphenylcyclopropenone in a Stabilized Gel to Treat Cutaneous Metastases
Status: Enrolling
Updated: 11/27/2017
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Evanston, IL
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Asheville, NC
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Bismarck, ND
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Sioux Falls, SD
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Annandale, VA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Los Angeles, CA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
San Francisco, CA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Norwalk, CT
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Norwalk, CT
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Stamford, CT
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Orlando, FL
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Tampa, FL
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
New York, NY
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Durham, NC
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Abington, PA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Abington, PA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Fort Sam Houston, TX
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
San Antonio, TX
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Green Bay, WI
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Milwaukee, WI
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
West Allis, WI
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
West Allis, WI
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Research Site
mi
from
New Lambton Heights,
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Research Site
mi
from
New Lambton Heights,
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Saint Louis Park, MN
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Florida Cancer Specialists - Tampa (Dr. MLK Blvd)
mi
from
Tampa, FL
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Florida Cancer Specialists - Tampa (Dr. MLK Blvd)
mi
from
Tampa, FL
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Texas Oncology - Baylor Sammons Cancer Center
mi
from
Dallas, TX
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Texas Oncology - Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Virginia Oncology Associates
mi
from
Norfolk, VA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy
mi
from
Leuven,
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy
mi
from
Leuven,
Click here to add this to my saved trials
Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers
A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers
Status: Enrolling
Updated:  11/27/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers
A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers
Status: Enrolling
Updated: 11/27/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Metformin for Rising PSA Remote Trial
M-RePoRT: Metformin - Rising PSA Remote Trial
Status: Enrolling
Updated:  11/27/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Metformin for Rising PSA Remote Trial
M-RePoRT: Metformin - Rising PSA Remote Trial
Status: Enrolling
Updated: 11/27/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Providence Holy Cross Cancer Center
mi
from
Mission Hills, CA
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Providence Holy Cross Cancer Center
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
University of California Davis Cancer Center
mi
from
Sacramento, CA
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Bay Medical
mi
from
Panama City, FL
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Bay Medical
mi
from
Panama City, FL
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Saint Anthony's Hospital at Saint Anthony's Health Center
mi
from
Alton, IL
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Saint Anthony's Hospital at Saint Anthony's Health Center
mi
from
Alton, IL
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Alexian Brothers Radiation Oncology
mi
from
Elk Grove Village, IL
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Alexian Brothers Radiation Oncology
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Oncology Center at Saint Margaret Mercy Healthcare Center
mi
from
Hammond, IN
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Oncology Center at Saint Margaret Mercy Healthcare Center
mi
from
Hammond, IN
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Cancer Center at Ball Memorial Hospital
mi
from
Muncie, IN
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Cancer Center at Ball Memorial Hospital
mi
from
Muncie, IN
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Regional Cancer Center at Singing River Hospital
mi
from
Pascagoula, MS
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Regional Cancer Center at Singing River Hospital
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Cancer Institute of Cape Girardeau, LLC
mi
from
Cape Girardeau, MO
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Cancer Institute of Cape Girardeau, LLC
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials